Wynzora

Wynzora combines betamethasone and calcipotriol for topical treatment of plaque psoriasis. This corticosteroid and vitamin D analogue reduces inflammation and skin cell overgrowth. Suitable for adults seeking localized relief from psoriasis symptoms. Wynzora cream offers a targeted approach to managing mild to moderate psoriasis.

Wynzora is used to treat plaque psoriasis in adults, helping to reduce redness, scaling, and thickness of skin plaques. It works by combining the anti-inflammatory effects of betamethasone with the skin cell regulation of calcipotriol. This combination therapy is designed for localized application on affected areas. Wynzora is not intended for widespread or severe psoriasis cases.

Wynzora cream is applied directly to psoriasis plaques to provide localized relief from symptoms like itching and inflammation. Users may notice reduced redness and smoother skin within a few weeks of consistent use. The medication works gradually to improve skin appearance without causing systemic effects typical of oral treatments. Some users report temporary skin dryness or mild irritation at the application site.

Wynzora is for external use only and should not be applied to broken or infected skin. Avoid contact with eyes, mouth, or other mucous membranes to prevent irritation. Do not use on large areas of the body or for prolonged periods without medical supervision. Keep the medication out of reach of children and pets. Consult a healthcare provider if irritation or worsening symptoms occur.

Wynzora may interact with other topical medications, especially those containing strong corticosteroids or vitamin D analogues. Avoid combining with other psoriasis treatments unless directed by a healthcare provider. No significant interactions with systemic drugs have been widely reported, but caution is advised when using multiple topical products simultaneously. Alcohol-based products may increase skin dryness when used concurrently.